Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2006-08-09
2010-11-30
Bristol, Lynn (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S155100
Reexamination Certificate
active
07842292
ABSTRACT:
The present invention provides methods and compositions for treatment of B-cell malignancies, including non-Hodgkin's lymphoma, comprising administering to a patient in need of the treatment a TACI-Ig fusion molecule in amount sufficient to suppress proliferation-inducing functions of BlyS and APRIL.
REFERENCES:
patent: 4331647 (1982-05-01), Goldenberg
patent: 4486533 (1984-12-01), Lambowitz
patent: 4579821 (1986-04-01), Palmiter et al.
patent: 4599311 (1986-07-01), Kawasaki
patent: 4601978 (1986-07-01), Karin
patent: 4615974 (1986-10-01), Kingsman et al.
patent: 4656134 (1987-04-01), Ringold
patent: 4661454 (1987-04-01), Botstein et al.
patent: 4713339 (1987-12-01), Levinson et al.
patent: 4784950 (1988-11-01), Hagen et al.
patent: 4845075 (1989-07-01), Murray et al.
patent: 4870008 (1989-09-01), Brake
patent: 4882279 (1989-11-01), Cregg
patent: 4931373 (1990-06-01), Kawasaki et al.
patent: 4935349 (1990-06-01), McKnight et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 4956288 (1990-09-01), Barsoum
patent: 4977092 (1990-12-01), Bitter
patent: 4990446 (1991-02-01), Oberto et al.
patent: 5037743 (1991-08-01), Welch et al.
patent: 5063154 (1991-11-01), Fink et al.
patent: 5139936 (1992-08-01), Botstein et al.
patent: 5143830 (1992-09-01), Holland et al.
patent: 5155027 (1992-10-01), Sledziewski et al.
patent: 5162222 (1992-11-01), Guarino et al.
patent: 5162228 (1992-11-01), Sumino et al.
patent: 5208146 (1993-05-01), Irie
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5403484 (1995-04-01), Ladner et al.
patent: 5523227 (1996-06-01), Bram et al.
patent: 5541291 (1996-07-01), Keene
patent: 5567584 (1996-10-01), Sledziewski et al.
patent: 5571698 (1996-11-01), Ladner et al.
patent: 5595721 (1997-01-01), Kaminski et al.
patent: 5637677 (1997-06-01), Greene et al.
patent: 5650550 (1997-07-01), Korach et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5716808 (1998-02-01), Raymond
patent: 5736383 (1998-04-01), Raymond
patent: 5739277 (1998-04-01), Presta et al.
patent: 5969102 (1999-10-01), Bram et al.
patent: 6015801 (2000-01-01), Daifotis et al.
patent: 6316222 (2001-11-01), Bram et al.
patent: 6500428 (2002-12-01), Bram et al.
patent: 6537540 (2003-03-01), Burstein et al.
patent: 6716576 (2004-04-01), Yu et al.
patent: 6774106 (2004-08-01), Theill et al.
patent: 7501487 (2009-03-01), Mangelsdorf et al.
patent: 2003/0022233 (2003-01-01), Goodwin et al.
patent: 2003/0103986 (2003-06-01), Rixon et al.
patent: 2004/0013674 (2004-01-01), Ambrose et al.
patent: 2005/0070689 (2005-03-01), Dixit et al.
patent: 2005/0163775 (2005-07-01), Chan et al.
patent: 2005/0183148 (2005-08-01), Bram et al.
patent: 2006/0034852 (2006-02-01), Rixon et al.
patent: 2006/0067933 (2006-03-01), Gross et al.
patent: 2006/0073146 (2006-04-01), Ashkenazi et al.
patent: 2006/0286093 (2006-12-01), Gross et al.
patent: 2007/0071760 (2007-03-01), Broly et al.
patent: 2007/0264689 (2007-11-01), Gross et al.
patent: 2007/0269443 (2007-11-01), Kalled et al.
patent: 2006201471 (2006-05-01), None
patent: 0869180 (1998-10-01), None
patent: 1666052 (2006-06-01), None
patent: 9828628.9 (1998-12-01), None
patent: WO 91/11465 (1991-08-01), None
patent: WO 94/06463 (1994-03-01), None
patent: WO 94/09137 (1994-04-01), None
patent: WO 95/35501 (1995-12-01), None
patent: WO 96/18641 (1996-06-01), None
patent: WO 96/27011 (1996-09-01), None
patent: WO 97/09137 (1997-03-01), None
patent: WO 97/17450 (1997-05-01), None
patent: WO 97/17451 (1997-05-01), None
patent: WO 97/33902 (1997-09-01), None
patent: WO 98/02536 (1998-01-01), None
patent: WO 98/02565 (1998-01-01), None
patent: WO 98/18921 (1998-05-01), None
patent: WO 98/27114 (1998-06-01), None
patent: WO 98/39361 (1998-09-01), None
patent: WO 98/55620 (1998-12-01), None
patent: WO 98/55621 (1998-12-01), None
patent: WO 99/04001 (1999-01-01), None
patent: WO 99/11791 (1999-03-01), None
patent: WO 99/12964 (1999-03-01), None
patent: WO 99/12965 (1999-03-01), None
patent: WO 00/03995 (2000-01-01), None
patent: WO 00/39295 (2000-07-01), None
patent: WO 00/40714 (2000-07-01), None
patent: WO 00/40716 (2000-07-01), None
patent: WO 00/43032 (2000-07-01), None
patent: WO 00/50597 (2000-08-01), None
patent: WO 00/62790 (2000-10-01), None
patent: WO 00/67034 (2000-11-01), None
patent: WO 01/12812 (2001-02-01), None
patent: WO 01/24811 (2001-04-01), None
patent: WO 01/60397 (2001-08-01), None
patent: WO 01/77342 (2001-10-01), None
patent: WO 01/81417 (2001-11-01), None
patent: WO 01/87977 (2001-11-01), None
patent: PCT/JP01/06944 (2002-02-01), None
patent: WO 02/14504 (2002-02-01), None
patent: WO 02/38766 (2002-05-01), None
patent: WO 02/066516 (2002-08-01), None
patent: WO 02/094852 (2002-11-01), None
patent: WO 03/001877 (2003-01-01), None
patent: WO 03/014294 (2003-02-01), None
patent: WO 03/055979 (2003-07-01), None
patent: WO 2005/005462 (2005-01-01), None
patent: WO 2005/042009 (2005-05-01), None
patent: WO 2006/052493 (2006-05-01), None
patent: WO 2006/068867 (2006-06-01), None
patent: WO 2007/019573 (2007-02-01), None
patent: WO 2007/019575 (2007-02-01), None
patent: WO 2007/019618 (2007-02-01), None
patent: WO 2007/134326 (2007-11-01), None
Martino, FierceBiotech, Press Release: ZymoGenetics and Serono to Begin TACI-Ig Clinical Studies in B-cell Malignancies, pp. 1-4, Nov. 9, 2006.
Burgess et al, Journal of Cell Biology 111:2129-2138 (Nov. 1990).
Lazar et al., Molecular and Cellular Biology 8(3) 1247-1252) (1988).
Schwartz et al., Proc Natl Acad Sci USA 84:6408-6411 (1987).
Lin et al Biochemistry USA 14:1559-1563 (1975).
U.S. Appl. No. 09/627,206, filed Jul. 2000, Gross, Jane.
Ibragimova and Eade (Biophysical Journal, Oct. 1999, vol. 77, pp. 2191-2198).
Smith et al. (Nature Biotechnology 15:1222-1223 (1997)).
Brenner (Trends in Genetics 15:132-133 (1999)).
Lee (Arch Pharm Res. 25(5):572-84 (2002)).
Ansell et al. (Clin. Cancer Res. 14(4):1105-1110 (Feb. 15, 2008)).
Barlogie, B., et al. Extended Survival in Advanced and Refractory Multiple Myeloma After Single-Agent Thalidomide: Identification of Prognostic Factors in a Phase 2 Study of 169 Patients, Blood, vol. 98, No. 2, pp. 492-494 (2001).
Do, R., “Attenuation of Apoptosis Underlies B Lymphocyte Stimulator Enhancement of Humoral Immune Response.” J. Exp. Med., vol. 192, No. 7, pp. 953-964 (2000).
Mackay, F., et al., “Mice Transgenic for BAFF Develop Lymphocytic Disorders Along with Autoimmune Manifestations,” J. Exp. Med., vol. 190, No. 11, pp. 1697-1710 (1999).
Moore, P., et al., “BLyS: Member of the Tumor Necrosis Factor Family and B Lymphocyte Stimulator,” Science, vol. 285, pp. 260-263 (1999).
Richardson, P., et al., “A Phase 2 Study of Bortezomib in Relapsed, Refractoroy Myeloma,” N Engl J Med, vol. 348, No. 26, pp. 2609-2617 (2003).
Schneider, P., et al., “BAFF, A Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth,” J. Exp. Med., vol. 189, No. 11, pp. 1747-1756 (1999).
Cheema, G., et al., “Elevated Serum B Lmphocyte Stimulator Levels in Patients With Systemic Immune-Based Rheumatic Diseases,” Arthritis & Rheumatism, vol. 44., No. 6, pp. 1313-1319 (2001).
Cheson, B., et al., “National Cancer Institute-Sponsored Working Group Guidelines for Chronic Lymphocytic Leukemia: Revised Guidelines for Diagnosis and Treatment,” Blood, vol. 87, No. 12, pp. 4990-4997 (1996).
Groom, J., et al., “Association of BAFF/BLyS Overexpression and Altered B Cell Differentiation With Sjogren's Syndrome,” The Journal of Clinical Investigation, vol. 109, No. 1, pp. 59-68 (2002).
Gross, J., et al., “TACI-Ig Neutralizes Molecules Critical for B Cell Development and Autoimmune Disease: Impaired B Cell Maturation in Mice Lacking BLyS,” vol. 15, pp. 289-302 (2001).
Gross, J., et al., “TACI and BCMA are Receptors for a TNF Homologue Implicated in B-Cell Autoimmune Disease,” Nature, vol. 404, pp. 995-999 (2000).
Hahne, M., et al., “APRIL, a New Ligand of the Tumor Necrosis Factor Family, Stimulates Tumor Cell Growth,” Journal of Experimental Medicine,
Ansell Stephen M.
Broly Herve
Busby Sharon J.
Nestorov Ivan
Öhrström Jan
Ares Trading S.A.
Bristol Lynn
Howrey LLP
Mayo Foundation for Medical Education and Research
Zymogenetics Inc.
LandOfFree
Methods for treating B-cell malignancies using a TACI-Ig... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating B-cell malignancies using a TACI-Ig..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating B-cell malignancies using a TACI-Ig... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4204063